6-fluoro-4-hydroxy-3-phenylquinolin-2(1H)-one | 144603-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-fluoro-4-hydroxy-3-phenylquinolin-2(1H)-one
• 英文别名: 6-fluoro-4-hydroxy-3-phenyl-1H-quinolin-2-one
• CAS: 144603-08-7
• 化学式: C₁₅H₁₀FNO₂
• 分子量: 255.248
• InChiKey: PAKRTZACNPEEEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-fluoro-4-hydroxy-3-phenylquinolin-2(1H)-one 在 potassium fluoride 、 磺酰氯 、 18-冠醚-6 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 6.17h， 生成 3,6-difluoro-3-phenyl-1H-quinoline-2,4-dione
  参考文献：
  名称：

  Halogenation reactions in position 3 of quinoline-2,4-dione systems by electrophilic substitution and halogen exchange

  摘要：

  3-Substituted 4-hydroxy-2(1 H)-quinolones 3, 5, 7 are halogenated with bromine or sulfuryl chloride to yield the quinolinediones 9 or 10. Reaction of 3, 5, 7 with chloroform gives the dichloromethyl quinolinediones 11. Halogen exchange leads from the chloro quinolinediones 10 to fluoro quinolinedones 12 and to azido quinolinediones 13. Similarly the dichloro quinolinedione 10 an reacts to the difluoro quinolinedione 14, which is reduced to the 3-fluoro-4-hydroxyquinolone 16 and reacts again with sulfuryl chloride to give the mixed 3-chloro-3-fluoroquinolinedione 15.

  DOI：

  10.1007/bf00816857
• 作为产物：
  描述：

  苯基丙二酸二乙酯 在 吡啶 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 6-fluoro-4-hydroxy-3-phenylquinolin-2(1H)-one
  参考文献：
  名称：

  Synthesis and SAR study of potent and selective PI3Kδ inhibitors

  摘要：

  2,3,4-Substituted quinolines such as (10a) were found to be potent inhibitors of PI3K delta in both biochemical and cellular assays with good selectivity over three other class I PI3K isoforms. Some of those analogs showed favorable pharmacokinetic properties. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.001

文献信息

• Efficient Preparation of 4-Hydroxyquinolin-2(1<i>H</i>)-one Derivatives with Silver-Catalyzed Carbon Dioxide Incorporation and Intramolecular Rearrangement
  作者：Tomonobu Ishida、Satoshi Kikuchi、Tohru Yamada

  DOI：10.1021/ol401571r

  日期：2013.7.19

  Although 4-hydroxyquinolin-2(1H)-one derivatives have attracted much attention due to their biological benefits, conventional reactions under harsh heat conditions must be employed to provide these key compounds. In the presence of a catalytic amount of silver salt, various o-alkynylanilines were treated with carbon dioxide and a base under mild reaction conditions to afford the corresponding 4-hy

  尽管4-羟基喹啉-2（1 H）-一衍生物由于其生物学优势而备受关注，但必须采用苛刻的加热条件下的常规反应来提供这些关键化合物。在催化量的银盐的存在下，在温和的反应条件下用二氧化碳和碱处理各种邻炔基苯胺，以高收率得到相应的4-羟基喹啉-2（1H）-一衍生物。
• Design, synthesis and antitubercular potency of 4-hydroxyquinolin-2(1H)-ones
  作者：Maíra Bidart de Macedo、Roman Kimmel、Damijana Urankar、Martin Gazvoda、Antonio Peixoto、Freya Cools、Eveline Torfs、Luc Verschaeve、Emerson Silva Lima、Antonín Lyčka、David Milićević、Antonín Klásek、Paul Cos、Stanislav Kafka、Janez Košmrlj、Davie Cappoen

  DOI：10.1016/j.ejmech.2017.06.061

  日期：2017.9

  None of these selected derivatives showed significant acute toxicity against MRC-5 cells or early signs of genotoxicity in the Vitotox™ assay at the active concentration range. The structure activity study relation provided some insight in the further favourable substitution pattern at the 4-hydroxyquinolin-2(1H)-one scaffold and finally 6-fluoro-4-hydroxy-3-phenylquinolin-2(1H)-one (38) was selected as

  在这项研究中，设计了一个由50个成员组成的，由4-羟基喹啉2（1 H）-取代基和两个密切相关的类似物组成的文库，对该文进行了计算机模拟评分，随后进行了合成。共有13个共有3-苯基取代基的13种衍生物对10μM以下的结核分枝杆菌H37Ra和牛分枝杆菌的抑制作用最小低于15μM的AN5A对快速生长的分枝杆菌物种无活性。在活性浓度范围内，在Vitotox™分析中，这些选择的衍生物均未显示出对MRC-5细胞具有明显的急性毒性或遗传毒性的早期迹象。结构活性研究的关系为4-羟基喹啉-2（1 H）-one支架和6-氟-4-羟基-3-苯基喹啉-2（1 H）-one（1 ）的进一步有利的取代方式提供了一些见识。38）被选为库中最有前途的成员，MIC为3.2μM，针对MRC-5的CC 50为67.4μM。
• Cu(i)-catalyzed chemical fixation of CO2 with 2-alkynylaniline into 4-hydroxyquinolin-2(1H)-one
  作者：Chun-Xiao Guo、Wen-Zhen Zhang、Si Liu、Xiao-Bing Lu

  DOI：10.1039/c3cy00858d

  日期：——

  copper(I) catalyzed reaction of 2-alkynylaniline with CO2 using DBU as base to produce 4-hydroxyquinolin-2(1H)-one derivatives in moderate to good yield is presented. In this reaction, a unique bond cleavage pattern for CO2 was observed that one of the C–O double bonds of CO2 was totally broken and rearranged into two moieties in the absence of the reductive reagent. This efficient reaction system showed

  提出了铜（Ⅰ）以DBU为碱催化2-炔基苯胺与CO 2的反应，以中等至良好的产率生成4-羟基喹啉-2（1H）-一衍生物。在该反应中，观察到了独特的CO 2键断裂模式：在不存在还原剂的情况下，CO 2的C–O双键之一被完全断裂并重排为两个部分。这种有效的反应体系显示出广泛的底物，包括硝基，溴，氰基和甲氧羰基。提出了一种可能的机制，其中包含异氰酸酯中间体。
• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Bui Minna

  公开号：US20100331306A1

  公开（公告）日：2010-12-30

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎性肠道疾病、炎性眼部疾病、炎性或不稳定膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症症状，包括但不限于自身免疫疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化、Sjogren综合症和自身免疫性溶血性贫血，包括各种过敏症状。本发明还提供了一种治疗与p110δ活性有关、依赖于或相关的癌症的方法，包括但不限于白血病，如急性髓细胞白血病（AML）、髓增生异常综合征（MDS）、髓增生性疾病（MPD）、慢性髓细胞白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体瘤，如乳腺癌。
• Synthesis and cytotoxic activity evaluation of indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones and 6-anilinoindoloquinoline derivatives
  作者：Yeh-Long Chen、Chao-Ho Chung、I.-Li Chen、Po-Hsu Chen、Haw-Yaun Jeng

  DOI：10.1016/s0968-0896(02)00111-6

  日期：2002.8

  Certain indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones 4a,b, 6, 8, 16a-c and 6-anilinoindoloquinoline derivatives 10a,b, 11a,b, 12a,b have been synthesized and evaluated in vitro against a 3-cell lines panel consisting of MCF7 (Breast), NCI-H460 (Lung), and SF-268 (CNS). Those active compounds 4a,b, 6, 8, 10a,b, 11a,b, 12a,b were then evaluated in the full panel of 60 human tumor cell lines derived from nine cancer cell types. The results have shown that cytotoxicity decreases in the order of 6-anilinoindoloquinolines>indoloquinolin-2(1H)-ones>pyrroloquinolin-2(1H)-ones>benzofuroquinolin-2(1H)-ones. Among them, 1-[3-(11H-indolo[3,2-c]quinolin-6ylamino)phenyl]ethanone oxime hydrochloride (14a) and its 2-chloro derivative (11b) were most active, with mean GI(50) values of 1.70 and 1.35 muM, respectively. Both compounds 11a,b were also found to inhibit the growth of SNB-75 (CNS cancer cell) with a GI(50) value of less than 0.01 muM, and, therefore, were selected for further evaluation for in vivo antitumor activity. (C) 2002 Published by Elsevier Science Ltd.